Sign up
Pharma Capital

Cellmid lays out major plan for product and distribution expansion

The company's shares are trading about 6% higher intra-day, at 46 cents.
Specifically formulated anti-aging hair solutions

Cellmid Limited (ASX:CDY) is anticipating a substantial increase in revenue in FY2019 following the planned expansion of distribution in the US and Japan and the increase in products in Australia.

USA - in-store placement from September 2018

Cellmid’s évolis range of products are specifically formulated anti-aging hair solutions which include shampoos, conditioners, sprays and activators.

For the first time évolis Professional products will be sold permanently in Neiman Marcus and Bloomingdales stores from September 2018.

The first Neiman Marcus stores designated for the full range of the évolis Professional products are Ala Moana (Hawaii), Fashion Island (California), Orlando (Florida), Northpark (Texas) and Houston (Texas).

These are flagship stores with well-trained sales associates and loyal customers.

READ: Cellmid secures partnership with Bloomingdales to sell évolis

Bloomingdales’ flagship store in New York will also carry the full évolis Professional range with other stores expected to come online in the next six months.

Japan - evolis launch in salons and pharmacies

The évolis branded FGF5 inhibitor anti-aging hair products will be launched in Japan in July 2018 (évolis Professional) and October 2018 (évolis pharmacy).

This is the first time that the Australian manufactured products will be exported to Japan and it follows a period of extensive product testing on Japanese customers assessing both beauty and therapeutic applications.

The sales channels for évolis Professional will be e-commerce and hair salons, while the évolis pharmacy range will be sold through independent chemists.

Australia and USA - new product launches

The évolis Professional range will be progressively introduced to suitable Australian pharmacies from July 2018.

This will increase the number of products sold from 4 to 15 within the brand in these pharmacies.

The évolis WHITE mask was launched in Australia in July 2018 and will be sold through pharmacies and salons in addition to Cellmid’s e-commerce platform.

Fillerina, the anti-aging transdermal filler product range with 11 variants, will be launched in Australian pharmacies progressively from September 2018.

Initial store locations have been secured with 70% of the first order already allocated to participating pharmacies.

The évolis Professional REVERSE Dry Shampoo is expected to be launched in Australia and USA in October 2018.

This product will be sold through all channels including premium retailers in the USA and pharmacies in Australia.

The évolis PROMOTE Protect spray will also be launched in beta test mode this month via e-commerce.

View full CDY profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.